Bio-Rad Launches The In2it A1C Analyzer For Point-Of-Care Diabetes Testing

Main Category: Medical Devices / Diagnostics
Also Included In: Diabetes
Article Date: 13 Nov 2007 - 4:00 PDT

email to a friend   printer friendly   opinions  

Bio-Rad Laboratories, Inc. (AMEX: BIO) and (AMEX: BIOb), a multinational manufacturer and distributor of life science research and clinical diagnostic products, announced the launch of the in2it™ analyzer for the "point-of-care" market. The in2it analyzer measures A1C, a well established indicator of a diabetic patient's glucose control, and offers healthcare professionals greater efficiency and convenience by providing laboratory-accurate A1C test results -- while the patient waits.

Designed for simplicity, convenience, and speed in near-patient testing, the in2it A1C analyzer is small, portable, and fully-automated, delivering results in minutes from a patient sample.

"The release of the in2it A1C analyzer is another example of Bio-Rad's continued commitment to provide the tools that help physicians, laboratories, and healthcare professionals provide better patient care to those affected by diabetes," said John Goetz, Bio-Rad Vice President and Group Manager Clinical Diagnostics.

About Bio-Rad

Bio-Rad Laboratories, Inc. (AMEX: BIO) and (AMEX: BIOb) has remained at the center of scientific discovery for more than 50 years manufacturing and distributing a broad range of products for the life science research and clinical diagnostic markets. The company is renowned worldwide among hospitals, universities, major research institutions, as well as biotechnology and pharmaceutical companies for its commitment to quality and customer service. Founded in 1952, Bio-Rad is headquartered in Hercules, California, and serves more than 85,000 research and industry customers worldwide through its global network of operations. The company employs over 6,300 people globally and had revenues of nearly $1.3 billion in 2006. For more information, visit http://www.bio-rad.com.

This release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements generally can be identified by the use of forward-looking terminology such as, "believe," "expect," "may," "will," "intend," "estimate," "continue," or similar expressions or the negative of those terms or expressions. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. For further information regarding the Company's risks and uncertainties, please refer to the "Risk Factors" in the Company's public reports filed with the Securities and Exchange Commission, including the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2006, as updated by subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. Bio-Rad Laboratories, Inc. disclaims any obligation to update these forward-looking statements.

Bio-Rad Laboratories

• Additional
• References
• Citations